Market Segmentation:
- By Treatment Type
- Medication
- Assisted Reproductive Technology (ART)
- Surgical Intervention
- Others (Lifestyle Modifications, Complementary Therapies)
- By Disease Indication
- Polycystic Ovary Syndrome (PCOS)
- Hypothalamic Amenorrhea
- Premature Ovarian Failure
- Hyperprolactinemia
- Thyroid Disorders
- Others (Obesity, Aging, Idiopathic)
- By Route of Administration
- Oral
- Injectable
- Implants
- Others (Transdermal, Vaginal)
- By End-user
- Hospitals
- Fertility Clinics
- Academic and Research Institutes
- Others (Home Care, Gynecology Centers)
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others (Direct Tenders, Specialty Clinics)
- By Regions
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Frequently Asked Questions
The current market size of the Anovulation industry is USD 1.2 billion in 2023.
Rising infertility rates, increasing awareness, lifestyle changes, technological advancements, rising disposable incomes, improving healthcare infrastructure, and favorable reimbursement policies.
High treatment costs, lack of awareness, social stigma, regulatory hurdles, limited access to healthcare facilities, and side effects of anovulation treatments.
The leading component segment in the Anovulation Market is the medication segment, which includes ovulation-inducing drugs like clomiphene citrate and letrozole.
Merck & Co., Inc., Ferring Pharmaceuticals, Bayer AG, Novartis AG, Pfizer Inc., Sanofi, Myovant Sciences Ltd., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Allergan plc.
The global Anovulation Market is expected to reach US$ 3.1 Bn in 2031, with a growth rate of 12.5% from 2024 to 2031.
Rising infertility rates, increasing awareness, lifestyle changes, technological advancements, rising disposable incomes, and improving healthcare infrastructure.